Author
Do Young Kim
Other affiliations: University of Ulsan, Fred Hutchinson Cancer Research Center, Kwandong University ...read more
Bio: Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Cirrhosis. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A simple-to-use risk score that uses baseline clinical variables was developed and validated and accurately estimates the risk of developing HCC at 3, 5, and 10 years in patients with chronic hepatitis B.
Abstract: Summary Background Therapy for chronic hepatitis B reduces the risk of progressing to hepatocellular carcinoma (HCC); however, there is no suitable and accurate means to assess risk. This study aimed to develop and validate a simple scoring system to predict HCC risk in patients with chronic hepatitis B. Methods The development cohort consisted of 3584 patients without cirrhosis from the community-based Taiwanese REVEAL-HBV study (of whom 131 developed HCC during follow-up), and a validation cohort of 1505 patients from three hospitals in Hong Kong and South Korea (of whom 111 developed HCC during follow-up). We used Cox multivariate proportional hazards model to predict risk of HCC at 3, 5, and 10 years. Variables included in the risk score were sex, age, serum alanine aminotransferase concentration, HBeAg status, and serum HBV DNA level. We calculated the area under receiver operating curve (AUROC) and calibration of predicted and observed HCC risk. Findings A 17-point risk score was developed, with HCC risk ranging from 0·0% to 23·6% at 3 years, 0·0% to 47·4% at 5 years, and 0·0% to 81·6% at 10 years for patients with the lowest and highest HCC risk, respectively. AUROCs to predict risk were 0·811 (95% CI 0·790–0·831) at 3 years, 0·796 (0·775–0·816) at 5 years, and 0·769 (0·747–0·790) at 10 years in the validation cohort, and 0·902 (0·884–0·918), 0·783 (0·759–0·806), and 0·806 (0·783–0·828), respectively, after exclusion of 277 patients in the validation cohort with cirrhosis. Predicted risk was well calibrated with Kaplan-Meier observed HCC risk. Interpretation A simple-to-use risk score that uses baseline clinical variables was developed and validated. The score accurately estimates the risk of developing HCC at 3, 5, and 10 years in patients with chronic hepatitis B. Clinicians can use this score to assess risk of HCC in patients with chronic hepatitis B and subsequently make evidence-based decisions about their clinical management. Funding The Academia Sinica; the National Health Research Institute, Taiwan; and Bristol-Myers Squibb.
532 citations
••
University of Miami1, Icahn School of Medicine at Mount Sinai2, Fourth Military Medical University3, Kyungpook National University Hospital4, University of Verona5, Samsung Medical Center6, Yonsei University7, Taipei Veterans General Hospital8, University of Pittsburgh9, University of Alcalá10, Bayer HealthCare Pharmaceuticals11, Bayer Corporation12, Newbury College13
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.
509 citations
••
Yonsei University1, University of Indonesia2, Aga Khan University3, University of Tartu4, Alfaisal University5, Ziauddin University6, Dubai Health Authority7, Shaikh Zayed Hospital8, Baqiyatallah University of Medical Sciences9, King Saud University10, King Saud bin Abdulaziz University for Health Sciences11, American University of Beirut12, Sungkyunkwan University13, University of Balamand14, Khyber Medical University15, University of Peshawar16, Reykjavík University17, RMIT University18, University of Ljubljana19, La Trobe University20, University of New South Wales21, University of Pécs22, University Medical Center Rizk Hospital23, University of Iceland24, Soonchunhyang University25, Cleveland Clinic26, Vilnius University27, Vilnius Gediminas Technical University28, University of Ulsan29, Tehran University of Medical Sciences30, Aims Community College31, University of Sydney32, Eijkman Institute for Molecular Biology33, Memorial Hospital of South Bend34, Pakistan Institute of Development Economics35, Military Hospital36, Saint Joseph's University37, Allama Iqbal Medical College38, Hiroshima University39, Lahore General Hospital40, Rawalpindi Medical College41, Holy Family Hospital42, Dow Medical College43
TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Abstract: The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
463 citations
••
TL;DR: The data suggest that LSM could be a useful predictor of HCC development in patients with chronic hepatitis B and together with old age, male sex, heavy alcohol consumption, serum albumin, and hepatitis B e antigen positivity, patients with a higher LSM were at a significantly greater risk of H CC development.
341 citations
••
TL;DR: In this paper, the influence of pore-size distribution of the diffusion layer on mass-transport problems of proton exchange membrane fuel cells (PEMFCs) is investigated using electrodes with hydrophobic diffusion layers.
325 citations
Cited by
More filters
01 Jan 2014
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Abstract: XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.
9,618 citations
••
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
01 Jan 2012
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Abstract: EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies recommended for patients with this type of cancer. This is the first European joint effort by the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC) to provide common guidelines for the management of hepatocellular carcinoma. These guidelines update the recommendations reported by the EASL panel of experts in HCC published in 2001 [1]. Several clinical and scientific advances have occurred during the past decade and, thus, a modern version of the document is urgently needed. The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data. Users of these guidelines should be aware that the recommendations are intended to guide clinical practice in circumstances where all possible resources and therapies are available. Thus, they should adapt the recommendations to their local regulations and/or team capacities, infrastructure, and cost– benefit strategies. Finally, this document sets out some recommendations that should be instrumental in advancing the research and knowledge of this disease and ultimately contribute to improve patient care. The EASL–EORTC CPG on the management of hepatocellular carcinoma provide recommendations based on the level of evidence and the strength of the data (the classification of evidence is adapted from National Cancer Institute [2]) (Table 1A) and the strength of recommendations following previously reported systems (GRADE systems) (Table 1B).
2,594 citations
••
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
2,491 citations